· Pharma · Pharma Desk
The oral GLP-1 battleground intensifies: Lilly's small-molecule Foundayo (orforglipron) squares off against Novo's oral peptide Wegovy pill, with Medicare Bridge Program formulary access now in play for both.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.